Objective To investigate the effect and safety of cytokine induced killer cells ( CIK cells) combined with chemotherapy in patients with advanced metastatic breast cancer .Methods Total of 124 patients with advanced metastatic breast cancer coming to Yingkou Central Hospital from Mar .2013 to Mar. 2015 were selected and were randomly divided into two groups by drawing method,control group and trial group,62 patients each.Conventional TA chemotherapy was applied to the control group.In addition to con-ventional TA chemotherapy,CIK cells for adoptive immunotherapy were applied to the trial group .The efficacy of the treatments were compared,the level of T cell subsets in the patients were measured before and after treatment,the toxicity of the treatments was analyzed ,and the safety of CIK cells combined with chemotherapy was evaluated.Results The objective response rate(ORR) and disease control rate(DCR) of the trial group were significantly higher than the control group(P<0.05);after the treatments,CD3+,CD3+/CD4+, CD3-/CD16+CD56+and CD4+/CD8+were significantly improved in the trial group(P<0.05) while CD3+/CD8+was significantly decreased(P <0.05).After treatment,CD3+,CD3+/CD4+,CD3-/CD16+CD56+, CD4+/CD8+of the trial group were higher than the control group[ (62.1 ±6.3)% vs (48.8 ±5.1)%, (42.5 ±6.1) vs (30.5 ±5.2),(26.3 ±6.2) vs (16.1 ±2.8),(1.62 ±0.21) vs (1.06 ±0.19)], CD3+/CD8+was lower than the control group[ (23.6 ±4.2) vs (30.2 ±5.9)],the differences between the two groups were significant ( P <0.01 ) .There was no significant difference in toxicity between the two groups(P>0.05).Conclusion CIK cells combined with chemotherapy in the treatment of advanced meta-static breast cancer has better ORR and DCR.It helps improve the immune function of patients while has no serious toxic reaction,which is safe and reliable and worthy of clinical promotion.%目的：探讨细胞因子诱导的杀伤细胞（ CIK细胞）配合化疗治疗转移性乳腺癌患者的效果及安全性。方法选择2013年3月至2015年3月在营口市中心医院进行治疗的晚期转移性乳腺癌患者124例，按照抽签法随机分为试验组和对照组，各62例。对照组给予常规表阿霉素联合多西他赛（ TA）化疗，试验组给予常规TA化疗加CIK细胞过继免疫治疗。比较两组患者的疗效；测定患者治疗前后T细胞亚群水平；分析两组患者的毒性反应发生情况及CIK细胞联合化疗的治疗安全性。结果试验组患者的客观缓解率（ORR）和疾病控制率（DCR）均显著高于对照组（P＜0.05）；治疗结束后，试验组患者的总 T 淋巴细胞（ CD3＋）、T 辅助细胞（ CD3＋／CD4＋）、自然杀伤细胞（ NK 细胞）（CD3－／CD16＋CD56＋）和免疫状态（CD4＋／CD8＋）均较治疗前显著提高（P＜0.01）；而T 抑制细胞（CD3＋／CD8＋）较治疗前显著降低（P＜0.05）；治疗后试验组 CD3＋、CD3＋／CD4＋、CD3－／CD16＋CD56＋、CD4＋／CD8＋高于对照组[（62.1±6.3）％比（48.8±5.1）％，（42.5±6.1）比（30.5±5.2），（26.3±6.2）比（16.1±2.8），（1.62±0.21）比（1.06±0.19）]，CD3＋／CD8＋低于对照组[（23.6±4.2）比（30.2±5.9）]，差异有统计学意义（P ＜0.01）。两组患者的毒性反应发生情况差异无统计学意义（P ＞0.05）。结论 CIK细胞联合化疗治疗晚期转移性乳腺癌的ORR和DCR都更好，提高了患者的免疫功能，无严重毒性反应，安全可靠，值得临床推广。
展开▼
